Olfr629, an integral member of the olfactory receptor family, plays a crucial role in the complex process of olfaction. As a G-protein-coupled receptor (GPCR), Olfr629 is situated within the nasal epithelium and is tasked with the recognition and transduction of odorant signals. The olfactory receptors, including Olfr629, share a common structural motif with other GPCRs, consisting of a 7-transmembrane domain architecture. This design facilitates their interaction with odorant molecules, initiating a cascade of events that leads to the perception of smell. The olfactory receptor gene family, including Olfr629, is recognized as the largest in the genome, underlining its significance in discerning a diverse array of olfactory stimuli.
Inhibition of Olfr629 involves a sophisticated interplay between various chemical compounds and cellular processes. The direct inhibitors act by either binding to the receptor site of Olfr629 or disrupting the olfactory signal transduction pathway, impeding the interaction with odorant molecules and hindering the initiation of the neuronal response responsible for smell perception. On the other hand, indirect inhibitors modulate specific signaling pathways associated with Olfr629, affecting intracellular events such as cAMP, calcium, JNK, NF-κB, and MAPK cascades. These intricate mechanisms of inhibition offer insights into potential strategies to modulate Olfr629 function, contributing to our understanding of the molecular basis of olfaction. The study of Olfr629 and its inhibition sheds light on the intricate interplay of biochemical and cellular processes involved in the olfactory system, providing a foundation for further exploration and refinement of olfactory modulation strategies.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin inhibits the PI3K/Akt pathway, which may indirectly affect Olfr629 through downstream signaling pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, potentially impacting Olfr629 by modulating the PI3K/Akt pathway and downstream signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that could indirectly influence Olfr629 by modulating the p38 MAPK pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor that may indirectly suppress Olfr629 by inhibiting the MAPK pathway and downstream signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, potentially affecting Olfr629 expression through its regulation of the mTOR pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that might indirectly influence Olfr629 through the JNK pathway and its downstream effects. | ||||||